Detection of receptor for advanced glycation end products (RAGE) and high mobility group protein box 1 HMGB1 levels in patients’ serum with breast cancer

Abstract

Abstract Background: Breast cancer (BC) is an unchecked proliferation of epithelial cells that begin in the breast lobules or ducts. BC develops and spreads as a result of the high mobility group protein box 1 (HMGB1). The survival, development, and metastasis of tumor cells have all been analyzed for the patients from Oncology Center in Merjan Medical City, Babylon Governorate. HMGB1 and receptor for advanced glycation end products (RAGE) levels in patients and controls were assessed using the enzyme-linked immunosorbent assay technique. Objectives: The current study’s goal is to analyze the blood levels of HMGB1 and RAGE in both BC patients and healthy volunteers and evaluate how their expression changes as the disease progresses. Materials and Methods: Samples collected from BC levels exhibited a 76% sensitivity and a 70% specificity, respectively. Serum RAGE levels were 74% sensitive and 70% specific for the diagnosis of BC, respectively, and their substantial P value = 0.023 correlated with tumor size. Results: Patients had significantly higher HMGB1 and RAGE levels than did the healthy control group. In order to identify BC, serum HMGB1 is linked to HMGB1 binding to the RAGE receptor. Conclusion: The presence of HMGB1 in the serum may serve as a helpful biomarker for the detection of BC. BC RAGE is useful for monitoring the growth of tumor size.